1. Home
  2. Investments
  3. Axion Biosystems

Instruments for customers in biopharma and academia

Axion at a glance

Axion Biosystems (“Axion”) is a global life science tools business headquartered in the US that develops, produces, and markets BEA (Bioelectronic Assay) and live-cell imaging instruments for customers in biopharma and academia. Axion’s products enable scientists to understand cell function in real-time, enabling research and the development of new therapies across various pharmaceutical segments (e.g., cell and gene therapies).

 

 

Year acquired
2021
Revenue
EUR 25.6m
Location
United States
Employees
142
Investment theme
Changing Demographics
SDG alignment

3, 9

What are the challenges Axion addresses

  • #1

    neurological conditions are the leading cause of ill health and disability worldwide and there are no treatments available to cure

  • 90%

    of drugs that pass through preclinical studies fail to meet the efficacy or safety margins required in subsequent trials

How does Axion help?

  • Reality today

    The live-cell perspective is not fully integrated in the development of therapies and scientists need better tools to understand cell function to target diseases and drive patient outcomes.

  • Axion approach

    Axion enables multi-dimensional, interoperable live-cell analysis to improve drug discovery and development without animal testing. Their products drive breakthroughs in cell and gene therapies across a wide spectrum of neurological research, ultimately leading to superior health outcomes.

  • Aspirational future

    Faster, more accurate and cost-efficient drug discovery and development for precision medicine through real-time understanding of cell functioning and enablement of cutting-edge fields within biotechnology and medicine that address various medical conditions such as cancer, genetic disorders, and autoimmune diseases.

  • Who is impacted?

    Researchers and biopharma are impacted directly by gaining insights through more effective tools that increase the understanding of cell functions. Patients are impacted indirectly through breakthroughs in treatment developments.

  • Contribution

    Axion enables academia and biopharma to gain insights into cell function, and thereby contributes to speeding up the time and increasing the quality of critical drug development.

  • Risks to impact

    Axion’s impact depends partly on how its customers in academia and biopharma choose to use its tools. Engaging with customers can help to ensure that the research and innovation it enables translates into patient outcomes downstream.

KPI reporting

Number of publications

Target 2027: 245

Change from '23-'24: +16%

2024
237
2023
204
2022
178

Number of publications measures the quantity of publications produced using Axion’s products, indicating contribution to research output on cell functioning.

Number of systems sold to Cell Gene Therapy (“CGT”) companies

Change from '23-'24: -48%

2024
14
2023
27
2022
22

Number of systems sold to CGT companies measures the enablement of companies operating in this cutting-edge field of biotechnology.

Number of experiments run

Target 2027: 1,045,000

Change from '23-'24: 0.2%

2024
851k
2023
853k
2022
790k

Number of experiments run quantifies the total count of scientific or research experiments­ conducted within a year, using Axion’s technology.